Research Article |
Corresponding author: Olena Popazova ( popazova.ea@gmail.com ) Academic editor: Plamen Peikov
© 2023 Olexiy Goncharov, Igor Belenichev, Andrii Abramov, Olena Popazova, Liudmyla Kucherenko, Nina Bukhtiyarova, Ivan Pavliuk.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Goncharov O, Belenichev I, Abramov A, Popazova O, Kucherenko L, Bukhtiyarova N, Pavliuk I (2023) Influence of experimental heart failure therapy with different generations of β-adrenergic blockers on Cardiac Electrical Activity (ECG) and Autonomic Regulation of Heart Rhythm (ARHR). Pharmacia 70(4): 1157-1165. https://doi.org/10.3897/pharmacia.70.e110924
|
Abstract: In the complex treatment of chronic heart failure (CHF) β-adrenoblockers (carvedilol, nebivolol, bisoprolol, metoprolol) are used, which due to their pharmacological properties increase the survival rate of patients, improve cardio- and haemodynamic parameters, metabolism. However, modern realities in medicine require creation of new more effective and safe β-adrenoblockers. In this regard, the potential drug Hypertirl is of interest. The aim was to evaluate the cardioprotective effect of 1-(b-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril) on cardiac electrical activity and autonomic regulation of heart rhythm in a model of CHF in comparison with β-adrenoblockers of different generations (Nebivolol, Carvedilol, Bisoprolol, Metoprolol).
Materials and methods: Chronic heart failure was induced by 14-day administration of doxorubicin in a cumulative dose of 15 mg/kg to white mongrel rats weighing 190–220g (total 85). The investigated drugs were administered after doxorubicin course for 30 days: Hypertril at an experimentally substantiated dose of 3.5 mg/kg, Metoprolol succinate 15 mg/kg, Nebivolol 10 mg/kg, Carvedilol 50 mg/kg, Bisoprolol 10 mg/kg. At the end of drug administration under thiopental anaesthesia (40 mg/kg), electrocardiogram (ECG) and autonomic regulation of heart rhythm (ARHR) were analysed using a computer analyser CardioCom-2000plus (KAI-Medica, Ukraine). The results of the study were calculated using a standard statistical package “STATISTICA for Windows 6.0” (StatSoftInc., №AXXR712D833214FAN5), “SPSS 16.0” and “Microsoft Office Excell 2003”.
Results and discussion: Hypertril administration resulted in a negative chronotropic effect, normalisation of atrial (P) and ventricular (R) spike amplitude, ST segment inversion below isoline, increased amplitude of ventricular myocardial repolarisation T. Myocardial repolarisation spike were observed, as well as normalised the duration of atrial (P) and ventricular depolarisation phase (QRS complex) to the intact value and restored the duration of electrical diastole (TR interval). Hypertril reduced systolic and diastolic myocardial dysfunction in animals with CHF. Hypertril restored autonomic mechanisms of heart rhythm regulation and balanced activity of sympathetic and parasympathetic parts of autonomic nervous system in the control of cardiac function.
Conclusion: The obtained results demonstrated the undoubted advantage of the new original molecule (Hypertril) over basic β-adrenoblockers (Metoprolol, Nebivolol, Carvedilol and Bisoprolol) and experimentally justify further in-depth study to create on its basis a drug for the treatment of CHF.
chronic heart failure, cardiac bioelectrical activity, β-adrenoblockers
Chronic heart failure (CHF) is one of the key clinical and economic problems for the healthcare systems of most developed countries in the world. It is characterized by a high prevalence and an unfavorable prognosis (
The Scientific and Production Association “Farmatron,” together with the Scientific and Technological Complex “Institute of Single Crystals” of the National Academy of Sciences of Ukraine, has developed methods for the synthesis and standardization of the substance “Hypertril” and the technology of parenteral solutions (Certificate No. 2, Series 020213). According to the decision of the State Expert Center of the Ministry of Health of Ukraine, the first phase has been successfully completed, and the second phase of clinical trials for the injection solution of Hypertril is underway. The aforementioned progress determines the prospects for studying oral forms of Hypertril as a promising agent in the comprehensive treatment of CHF.
To evaluate the cardioprotective effect of 1-(b-phenylethyl)-4-amino-1,2,4-triazolium bromide (Hypertril) on cardiac electrical activity and autonomic regulation of heart rhythm in the model of CHF in comparison with β-adrenoblockers of different generations (Nebivolol, Carvedilol, Bisoprolol and Metoprolol).
The experiments were carried out on 85 white outbred rats weighing 190–220 g, obtained from the vivarium of the Institute of Pharmacology and Toxicology of the Academy of Medical Sciences of Ukraine and the Institute of Physiology. A.A. Bogomolets of the Academy of Medical Sciences of Ukraine. The duration of the quarantine (acclimatization period) for all animals was 14 days. During quarantine, each animal was examined daily (behavior and general condition), animals were observed twice a day in cages (morbidity and mortality). Before the start of the study, animals that met the inclusion criteria in the experiment were divided into groups using the randomization method. Throughout the experiment, the animals were observed, death was recorded, and their appearance was described. All manipulations were carried out in accordance with the provisions on the collection of animals for biomedical experiments (Strasbourg 1986, as amended in 1998) and the “European Applicable Protection of Vertebrate Animals used for Experimental and Scientific Purposes”. The protocols of experimental studies and their results were approved by the decision of the Commission on Bioethics of ZSMU (Protocol No. 3 dated March 22, 2021).
Doxorubicin model was used to reproduce chronic heart failure (
The study used Doxorubicin “Ebeve” 50 mg/25 ml (EBEWE Pharma Ges.mbH Nfg. KG, Austria. All preparations were administered intragastrically once a day in the form of a suspension of 1% starch mucus for 30 days after a 14-day administration of doxorubicin – Hypertril at an experimentally substantiated dose of 3.5 mg/kg (
At the end of the experiment, in animals under anesthesia (sodium ethaminal, 40 mg/kg), the heart was taken and weighed, and blood was taken from the abdominal artery with a syringe for biochemical studies.
In all groups of animals on the 45th day of the experiment under thiopental anaesthesia (40 mg/kg) electrocardiogram (ECG) and autonomic regulation of heart rhythm (ARHR) were analysed using a computer analyser CardioCom-2000plus (KAI-medica, Ukraine).
When analysing ECG, the parameters of clips and intervals were calculated as the average value of their amplitude or duration module, respectively, in all recorded leads.
In addition, ECG in the 2nd standard lead was recorded for 5 minutes (at least 1000 cardio intervals) to study autonomic regulation of heart rhythm (ARHR) The method allows to estimate the functional state of activity of sympathetic (adrenergic) and parasympathetic (cholinergic) departments of the autonomic nervous system on the sinus node (
All calculations were carried out using the original computer programme.
The results of the study were calculated using a standard statistical package “STATISTICA for Windows 6.0” (StatSoftInc., №AXXR712D833214FAN5), “SPSS 16.0” and “Microsoft Office Excell 2003”. To determine the presence and nature of the relationship between numerical variables, a regression analysis procedure was used using linear, logarithmic, power, exponential, polynomial (second and third degree) models, achieving an independent (according to the Durbin-Watson criterion), normal distribution of residuals (at the same time as skewness and kurtosis values were used for the goodness of fit criterion. Distribution normality was assessed using the Shapiro-Wilk test. The data were presented as an average value. The significance of negativity between the mean values was determined by Student’s t-test (in the case of a normal distribution). The Mann-Whitney U-test was used in the case of a distribution that is negative compared to normal or analysis of ordinal variables. To compare independent variables in more than two samples, analysis of variance (ANOVA) was used with a normal distribution or the Kruskal-Wallis test for a distribution that was negative from normal.
The analysis of myocardial electrical activity in the control group of rats under light anesthesia, recorded in the second standard lead, exhibited a regular heart rhythm. The R wave showed higher amplitude compared to other ECG waveforms, and the ST segment was slightly below the baseline (-0.006±0.009 mV). In terms of ECG structure (Table
ECG parameters | Research series | |||
---|---|---|---|---|
Intact(1) | CHF (2) | CHF + Metoprolol(3) | CHF + Hypertril(4) | |
HR, min-1 | 378±4 | 497±61,3,4,5,6,7 | 437±61,2,4 | 400±21,2,3,5,6,7 |
Amplitude, mV | ||||
P | 0.048±0.004 | 0.019±0.0051,4,5,6,7 | 0.032±0.0031,4,6,7 | 0.061±0.0042,3,5 |
R | 0.371±0.027 | 0.202±0.0131,4,5,6,7 | 0.192±0.011,4,5,6,7 | 0.359±0.0332,3 |
T | 0.114±0.009 | 0.066±0.0151,3,4,5,6,7 | 0.059±0.0111,4,5,6,7 | 0.148±0.0101,2,3 |
ST | -0.006±0.009 | 0.103±0.0081,3,4,5,6,7 | 0.029±0.0111,2,4,6,7 | -0.013±0.0082,3 |
Cardiac cycle duration, ms | ||||
RR | 159.9±1.7 | 122.5±1.61,3,4,5,6,7 | 137.1±1.81,2,4 | 149.4±1.01,2,3 |
CHF(2) | CHF + Bisoprolol(5) | CHF + Nebivolol(6) | CHF + Carvedilol(7) | |
HR, min-1 | 497±61,3,4,5,6,7 | 425±91,2,4 | 431±101,2,4 | 424±101,2.4 |
Amplitude, mV | ||||
P | 0.019±0.0051,4,5,6,7 | 0.044±0.0052,4 | 0.055±0.0082,3 | 0.064±0.0102,3 |
R | 0.202±0.0131,4,5,6,7 | 0.359±0.0332,3 | 0.398±0.0332,3 | 0.318±0.0402,3 |
T | 0.066±0.0151,3,4,5,6,7 | 0.148±0.0101,2,3,4 | 0.152±0.0252,3 | 0.165±0.0221,2,3 |
ST | 0.103±0.0081,3,4,5,6,7 | -0.022±0.0342 | -0.021±0.0212,3 | -0.058±0.0392,3 |
Cardiac cycle duration, ms | ||||
RR | 122.5±1.61,3,4,5,6,7 | 145.4±4.41,2 | 142.9±3.11,2 | 143.3±4.41,2 |
SDNN | 1.547±0.1921 | 1.726±0.181 | 1.800±0.245 | 1.957±0.223 |
Interval duration, % of cardiac cycle duration RR | ||||
P | 17.956±0.3641,3,4,5,6,7 | 12.282±0.8271,2,4 | 13.186±0.3161,2,4 | 13.209±0.7291,2 |
PQ | 8.538±0.4403,4,5,6,7 | 12.196±0.9351,2,4 | 11.005±0.9942,4 | 11.046±0.7561,2,4 |
QRS | 21.520±0.6421,3,4,5,7 | 14.317±0.9431,2,3,4,6 | 22.917±0.5571,2,3,4,5,7 | 16.626±0.8262,3,6 |
Т | 30.280±0.9671,3,4,5,6,7 | 22.724±1.2912,3,4,6 | 17.685±0.8161,3,4,5,7 | 22.952±1.1832,3,4,6 |
ТР | 21.704±1.2401,4,5,6,7 | 38.478±1.6851,2,3,4 | 35.204±1.6232,3 | 36.164±1.5792,3 |
The induction of heart failure in rats resulted in an increased heart rate by 31.5% and a shortened RR interval (duration of the cardiac cycle) by 23.8% compared to the control group. ECG recordings of animals with heart failure exhibited a 59% reduction in the amplitude of P waves, as well as more than 40% reduction in R and T wave amplitudes, indicating a decreased contractile function of the myocardium (inotropic dysregulation) and a potential decrease in stroke volume. In terms of ECG structure (Table
The development of CHF in experimental animals was also accompanied by dysregulation of vegetative function of the heart, which were accompanied by a significant, about 4-fold, decrease in spectral power of heart rhythm TPW with a 5-fold increase in stress index SI. The absolute power of high-frequency component HF, which characterizes the influence of parasympathetic regulatory component on HRV, decreased nearly 3-fold and the absolute power of low-frequency component LF, which characterizes the influence of sympathetic regulatory component on HRV, decreased 2.5-fold. At the same time, the balance of sympathetic and parasympathetic regulation LF/HF decreased in 2 times (PST<0,001) on a background of the decrease of spectral power of heart rhythm. The obtained data testify to the fact that CHF development in experimental animals was accompanied by compensatory predominance of parasympathetic regulation of cardiac cycle by vagus nerve in response to tachycardia and decreased spectral power of ARHR (Table
Effect of drugs on spectral characteristics of autonomic regulation of heart rhythm (ARHR) (M±m).
ARHR indicators | Research series | |||
---|---|---|---|---|
Intact (1) | CHF (2) | CHF + Metoprolol (3) | CHF + Hypertril (4) | |
PSD, ms2 | 4.007±0.495 | 0.984±0.185 1,4,5 | 1.585±0.301 1,4 | 2.920±0.395 2,3,5,6,7 |
ULF, ms2 | 2.057±0.343 | 0.373±0.074 1,4 | 0.664±0.180 1 | 1.283±0.266 2,5,6,7 |
VLF, ms2 | 1.565±0.168 | 0.615±0.167 1,4 | 0.721±0.130 1,4 | 1.333±0.154 2,3 |
LF, ms2 | 1.353±0.243 | 0.528±0.126 1,4 | 0.549±0.182 1,4 | 1.623±0.264 2,3,5,6,7 |
HF, ms2 | 0.572±0.097 | 0.203±0.037 1,4 | 0.329±0.075 4,5,6,7 | 0.663±0.099 2,3,5,6,7 |
LF norm, % | 70.884±1.318 | 50.984±4.370 1,4,5,6,7 | 60.878±4.862 4,5,6 | 71.441±0.684 2,3,5 |
HF norm, % | 29.115±1.318 | 49.015±4.370 1,4,5,6,7 | 39.121±4.862 4,5,6 | 28.558±0.684 2,3,5 |
LF/HF (norm) | 2.624±0.176 | 1.404±0.240 1,4,5,6,7 | 2.002±0.284 5,6,7 | 2.545±0.080 2,5 |
CHF (2) | CHF + Bisoprolol (5) | CHF + Nebivolol (6) | CHF + Carvedilol (7) | |
PSD, ms2 | 0.984±0.185 1,4,5 | 1.785±0.341 1,2,4 | 1.150±0.177 1,4 | 1.328±0.15 1,4 |
ULF, ms2 | 0.373±0.074 1,4 | 0.442±0.112 1,4 | 0.420±0.141 1,4 | 0.464±0.129 1,4 |
VLF, ms2 | 0.615±0.167 1,4 | 0.978±0.231 1 | 0.970±0.326 | 1.114±0.299 |
LF, ms2 | 0.528±0.126 1,4 | 0.387±0.044 1,4 | 0.310±0.070 1,4 | 0.300±0.057 1,4 |
HF, ms2 | 0.203±0.037 1,4 | 0.139±0.011 1,3,4 | 0.150±0.016 1,3,4 | 0.128±0.012 1,3,4 |
LF norm, % | 50.984±4.370 1,4,5,6,7 | 74.328±0.262 1,2,3,4 | 72.390±2.414 2,3 | 72.450±2.927 2 |
HF norm, % | 49.015±4.370 1,4,5,6,7 | 25.671±0.262 1,2,3,4 | 27.610±2.414 2,3 | 27.550±2.927 2 |
LF/HF | 1.404±0.240 1,4,5,6,7 | 2.884±0.038 2,3,4 | 2.820±0.262 2,3 | 3.200±0.487 2,3 |
IC | 0.231±0.043 6 | 0.350±0.059 3,4 | 0.630±0.172 1,2,3,4 | 0.457±0.125 3 |
SI | 42154±4752 1,4,5,6,7 | 19144±803 1,2,3,4 | 19477±3648 1,2 | 20537±608 1,2,3,4 |
APR | 739±43 1,4,5,6 | 501±27 2,3,7 | 537±43 2,3 | 624±40 3,5 |
Ranking of β-adrenoblockers of different generations (Carvedilol, Bisoprolol, Nebivolol, Metoprolol, Hypertril) by efficacy in experimental CHF.
Indicator ranks | Intact | CHF | Metoprolol | Hypertril | Bisoprolol | Nebivolol | Carvedilol |
---|---|---|---|---|---|---|---|
Chronotropic function of the myocardium | 3 | 1 | 1.5 | 2 | 1.5 | 1.5 | 1.5 |
Myocardial inotropic function | 3.5 | 1 | 1.5 | 4 | 3.5 | 3.5 | 4 |
Autonomic regulation of heart rhythm | 3.5 | 1 | 1.5 | 3.5 | 2 | 2 | 2 |
Thus, the complex of revealed changes demonstrates the disturbance of cardiac electrical work (according to ECG – disturbance of automaticity, conduction and contractility) and neurogenic mechanisms of its regulation (according to HRV – decentralization of neurogenic regulation circuits, reduction of spectrum power and increase of stress index) can in this case be considered as a manifestation of systolic and diastolic dysfunction in animals with experimental CHF.
The administration of Metoprolol to animals with heart failure resulted in a negative chronotropic effect, reducing heart rate by 12% (РST<0.001). However, this value remained 16% higher (РST<0.001) compared to animals in the intact group. In the group receiving Metoprolol, a significant decrease in the level of ST segment elevation was observed (more than 3 times compared to untreated animals), indicating potential anti-ischemic effects of the drug. There was also a slight increase in the amplitude of the P wave (depolarization of the atria), although its magnitude remained lower (РST=0.01) compared to intact rats, along with a shortening of its duration (РST<0.001) both in relation to untreated animals and intact rats. Metoprolol did not affect the amplitude of the QRS complex (ventricular depolarization), but partially normalized the duration of ventricular systole (РST=0.005 compared to animals with heart failure). Metoprolol had minimal impact on the amplitude of the T wave (myocardial repolarization) and the duration of the electrical diastole (TR interval). Therefore, Metoprolol exerted a moderate negative chronotropic effect and had a significant impact on neither systolic nor diastolic dysfunction of the heart.
Introduction of Metoprolol to animals with CHF practically did not affect the spectral power of heart rate TPW (РST >0.05) and the stress index SI (РST >0.05), as well as the centralization index IC (РST >0.05) and the index of vagosympathetic interaction LF/HF (РST >0.05). In other words, the introduction of Metoprolol to animals with HF did not have a significant impact on the balance of autonomic mechanisms regulating heart rate in experimental pathology.
The administration of Hypertril had a negative chronotropic effect on animals with HF, leading to a decrease in heart rate (HR) by 20% (РST <0.001), which was only 6% higher than in intact animals (РST <0.001). After the administration of Hypertril, the electrocardiogram (ECG) showed normalization of the amplitude of atrial (P) and ventricular (R) waves (РST >0.05), while the amplitude of the myocardial repolarization wave T increased by 30% and exceeded the values in intact rats, which could be attributed to improved myocardial energy supply and more rational use of macroergs for the contractile function of the heart. Indirect confirmation of this assumption was the inversion of the ST segment below the isoline, reaching the levels of intact animals (РST>0.05). The administration of Hypertril normalized the duration of the depolarization phase of the atria (P wave) and ventricles (QRS complex) to intact values (РST >0.05) and restored the duration of the electrical diastole (TR interval, РST >0.05). At the same time, the duration of the atrioventricular segment PQ was shortened and became 40% shorter (РST <0.001) than in control rats. The obtained data apparently indicate that experimental therapy with Hypertril significantly reduced systolic and diastolic myocardial dysfunction in animals with HF.
The administration of Hypertril to animals with HF significantly increased the spectral power of heart rate TPW by 3 times (РST <0.001 compared to untreated animals and РST >0.05 compared to intact rats) and reduced the stress index SI by 2.6 times (РST <0.001), which, nevertheless, remained 1.8 times higher than in intact animals (РST <0.001). Hypertril in animals with HF contributed to an increase in the power of sympathetic (LF) and parasympathetic (HF) regulation of HRV to the levels of the intact group and normalized the index of vagosympathetic interaction LF/HF (РST >0.05 compared to control animals). Thus, the administration of Hypertril to animals with HF indicated a significant restoration of the autonomic mechanisms regulating heart rate and a balance in the activity of the sympathetic and parasympathetic branches of the autonomic nervous system in controlling heart function.
The administration of Bisoprolol had a negative chronotropic effect on rats with HF and reduced heart rate (HR) by 15% (РST <0.001). However, HR remained 12% higher (РST <0.001) than in the intact group of animals. The ECG showed normalization of the amplitude of atrial (P) and ventricular (R) waves (РST >0.05 compared to intact animals), while the amplitude of the myocardial repolarization wave T increased and was 1.5 times higher than the values in intact rats (РST <0.02). The administration of Bisoprolol reduced the amplitude of the ST segment, which became negative, and its amplitude, although lower compared to intact animals, did not show statistically significant differences (РST >0.05). The ECG showed a shortening of the duration of the atrial depolarization wave P, ventricular depolarization complexes QRS, and repolarization wave T, as well as an increase in the duration of the electrical diastole TR (РST <0.001 compared to untreated animals with HF and РST <0.02 compared to intact animals).
The administration of Bisoprolol to animals with HF led to an increase in the spectral power of heart rate TPW by 80% (РST <0.001), which remained 65% lower in absolute values than in the intact group (РST <0.001). Bisoprolol did not affect the indices of sympathetic (LF) and parasympathetic (HF) regulation of HRV and contributed to the restoration of the index of vagosympathetic interaction LF/HF (РST >0.05 compared to intact animals). The stress index SI decreased significantly during therapy with Bisoprolol in animals with HF but remained approximately three times higher (РST <0.001) than in intact animals.
The administration of Nebivolol to rats with HF had a negative chronotropic effect, reducing heart rate (HR) by 13% (РST <0.001) while maintaining this parameter 14% higher (РST<0.001) than in the intact group of animals. Nebivolol led to the normalization of the amplitude of atrial (P) and ventricular (R) waves, as well as the repolarization wave T of the ventricular myocardium (РST >0.05 compared to intact animals) in rats with HF. However, the administration of the drug reduced the amplitude of the ST segment, which became negative, and its amplitude, although lower compared to intact animals, did not show statistical differences (РST >0.05). The administration of Nebivolol to animals with HF accelerated the depolarization time of the atria (P wave) and the ventricular repolarization complex (T), which were 13% and 29% shorter (РST <0.001), respectively, than in the intact group of rats. At the same time, the relative duration of the QRS complex did not differ from the values in untreated rats, while the time of atrioventricular conduction (PQ segment) and the duration of the electrical diastole TR were normalized to the intact level (РST >0.05).
The administration of Nebivolol to rats with HF did not affect the spectral power of heart rate TPW (РST >0.05), which remained 71% lower (РST<0.001) than in the intact group. Although the administration of Nebivolol to rats with HF did not have a statistical impact on the absolute spectral power indices of sympathetic (LF) and parasympathetic (HF) regulation of ARHR, there was an increase in the normalized power of sympathetic regulation (LF norm) and a decrease in the power of parasympathetic regulation (HF) of HRV (РST <0.001). This contributed to the normalization of the index of vagosympathetic interaction LF/HF (РST >0.05 compared to intact animals) and a significant increase in the index of centralization of regulatory systems IC (РST>0.05). The stress index SI decreased significantly during treatment with Nebivolol in animals with HF, but it remained 2.3 times higher (РST <0.002) than in intact animals.
The administration of Carvedilol had a negative chronotropic effect on rats with HF, reducing heart rate (HR) by 15% (РST <0.001) while maintaining this parameter 12% higher (РST <0.001) than in the intact group of animals. Carvedilol led to an increase in the amplitude of atrial (P) and ventricular (R) waves in animals with HF (by 3.3 times and 57%, respectively), as well as an increase in the amplitude of the myocardial repolarization wave T, which was 45% higher than in intact animals (РST <0.05). However, the administration of Carvedilol reduced the amplitude of the ST segment, which became negative, and its amplitude was comparable to that of intact animals (РST >0.05). Experimental therapy with Carvedilol contributed to the normalization of the duration of the electrical systole (QRS complex) and the repolarization time of the ventricles (T), as well as the duration of the electrical diastole of the heart (TR interval) (РST>0.05 compared to the intact group of rats). At the same time, there was a statistically significant reduction in the relative duration of the atrial electrical systole (P wave) and an increase in the atrioventricular conduction delay (PQ segment) compared to untreated (РST <0.005) and intact (РST <0.02) animals.
The administration of Carvedilol to rats with HF did not have a significant impact on the spectral power of heart rate TPW, which remained 67% lower (РST <0.001) than in the intact group and did not show statistical differences (РST >0.05) compared to untreated rats. The administration of Carvedilol to rats with HF did not statistically affect the absolute spectral power indices of sympathetic (LF) and parasympathetic (HF) regulation of HRV (РST >0.05). However, there was an increase in the normalized power of sympathetic regulation (LF norm) and a decrease in the power of parasympathetic regulation (HF) of HRV (РST <0.001), which contributed to the normalization of the index of vagosympathetic interaction LF/HF (РST >0.05 compared to intact animals). The stress index SI decreased significantly during treatment with Carvedilol in animals with HF but remained 2.4 times higher (РST <0.001) than in intact animals.
Principle: For ranking, we took the mean values of the values and calculated the modulus of the difference with the values of animals with CHF. In this case, the index in the CHF group was “0”. The obtained results were sorted in ascending order, i.e., the more the indicator differed from “CHF”, the higher rank it received. The sum of the ranks in each group was normalised by the total rank in the CHF group. The rank in the intact group of animals is also given for comparison.
The β-adrenoblockers (Carvedilol, Bisoprolol, Metoprolol, Nebivolol) studied in this work are the main agents of standard therapy of heart failure (
Since NO is an important mediator of vasodilation, its deficiency plays a key role in the processes of arterial hypertension development, impaired arterial tone, decreased coronary reserve, left ventricular hypertrophy and formation of left ventricular diastolic dysfunction. Changes in the system of endogenous nitric oxide were revealed in patients with CHF. Cardiomyocytes express two types of nitric oxide synthases (NOS): eNOS and iNOS. The activity of eNOS is regulated through myocardial contractile state, whereas iNOS is induced by cytokines. In CHF, under the influence of AOS, eNOS expression decreases and the concentration of necessary NO synthase cofactors decreases, and NO deficiency is observed (
IL-1β, TNF-a, INF (interferon) stimulate NO synthesis in cardiomyocytes by induction of iNOS during eNOS deprivation and activation of oxidative stress production of cytotoxic forms of NO. Cytotoxic forms of NO have a direct toxic effect on the myocardium, activates the processes of interstitial growth and fibrosis, which increases the negative inotropic effect of NO on the myocardium and causes geometric remodelling of the heart (
Thus, the obtained results demonstrated the undoubted advantage of the new original molecule (Hypertril) over the basic β-adrenoblockers (Metoprolol, Nebivolol, Carvedilol and Bisoprolol) and experimentally justify further in-depth study to create on its basis a drug for the treatment of CHF.